GlassScriptPhysician profile
Sofiya Kuras
NPI 1437227691
$7,175.04
in general payments reported to CMS, 2019-2025
28 companies · $1,549 in 2025
The $1,549 reported for 2025 was more than what 88% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,367 · 2022: $1,493 · 2023: $1,426 · 2024: $1,339 · 2025: $1,549.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,242 · Education: $71.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,242.27 |
| Education | $71.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,580.03 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $966.93 | 2021-2025 | Verquvo, Capvaxive, Belsomra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $798.32 | 2021-2025 | Jardiance, Ofev |
| E.R. Squibb & Sons, L.L.C. | $669.20 | 2021-2025 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals LP | $403.56 | 2021-2024 | Farxiga |
| Amgen INC. | $329.74 | 2021-2023 | Repatha |
| Sanofi-Aventis U.S. LLC | $304.07 | 2021-2024 | |
| Edwards Lifesciences Corporation | $256.28 | 2023-2025 | Sapien 3 Ultra Resilia |
| Verona Pharma, INC. | $231.29 | 2025 | Ohtuvayre |
| Bayer Healthcare Pharmaceuticals INC. | $198.00 | 2021-2022 | |
| Actelion Pharmaceuticals US, INC. | $185.93 | 2025 | Opsumit, Uptravi |
| Esperion Therapeutics, INC. | $167.20 | 2021-2025 | Nexletol |
| Amarin Pharma, INC. | $141.55 | 2021-2023 | |
| Pfizer INC. | $135.31 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $127.01 | 2021-2023 | Evkeeza |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $105.31 | 2021-2024 | Yupelri |
| Glaxosmithkline, LLC. | $105.18 | 2021-2025 | Nucala |
| Medtronic, INC. | $97.05 | 2021-2024 | Corevalve Evolut R, Mycarelink |
| Heartflow, INC. | $88.41 | 2024-2025 | |
| Scpharmaceuticals INC. | $69.17 | 2023-2024 | |
| Insmed, INC. | $49.77 | 2022 | |
| Medicomp INC | $30.93 | 2025 | Telepatch Cardiac Monitor |
| United Therapeutics Corporation | $26.69 | 2025 | Tyvaso |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $26.24 | 2021 | |
| Philips North America LLC | $23.87 | 2024 | (Ck7) Extended Holter |
| Kiniksa Pharmaceuticals International, Plc | $23.11 | 2024 | Arcalyst |
| Kiniksa Pharmaceuticals, LTD. | $21.00 | 2023 | Arcalyst |
| Kowa Pharmaceuticals America, INC. | $13.89 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sofiya Kuras listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.